"I’ve always been driven by the challenge and excitement of scientific discovery in the service of helping patients with serious diseases.
This has led me to platform-based biotechnology companies with innovative approaches to accessing and unlocking the potential of novel disease-modifying targets where I can help build the scientific and clinical capabilities needed to develop drugs that can transform the lives of patients."

Jared Gollob, MD

Chief Medical Officer

Jared is a seasoned leader in the biopharmaceutical industry, successfully bringing novel medicines through all phases of clinical trials and global regulatory approvals. In his role as CMO, Jared leads clinical development for Kymera, and has advanced multiple programs into the clinic across a variety of indications and continues to progress candidates identified by Kymera’s unique targeted protein degradation platform. Jared joined Kymera from Alnylam Pharmaceuticals, where he was Vice President of Clinical Development and Global Vice President of Medical Affairs for Amyloidosis. There, he led early and late stage clinical programs in infectious disease, oncology, and amyloidosis that provided the first proof of concept in humans for RNA interference therapeutics and culminated in the FDA and EMA approvals of ONPATTRO for the treatment of hereditary transthyretin amyloidosis. Jared previously held academic positions at Harvard Medical School and Duke University School of Medicine, and was on staff at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Duke University Medical Center, where he was engaged in both clinical and laboratory research in oncology and immunology. He has authored more than 50 peer-reviewed papers published in top-tier medical and scientific journals. Jared received his BA and MD from Columbia University, and completed clinical training in internal medicine and medical oncology at Massachusetts General Hospital and the Dana-Farber Cancer Institute, respectively.

More Information
Key Facts
Hear from Jared